Perrigo New Products Include Branded Weight-Loss Supplement, Kid’s Multi
This article was originally published in The Tan Sheet
Executive Summary
Perrigo introduced two branded products developed in-house at the National Association of Chain Drug Stores Marketplace June 8-10: Dr. Steven Rosenblatt's Ephedra Free Starch Blocker with Phase 2 Starch Neutralizer and Sesame Street Complete Children's Multivitamin Multimineral Supplement
You may also be interested in...
NACDS In Brief
Perrigo: Private label CoQ10 and fish oil introduced under out-licensed combination-of-matter patent, the firm announces at the NACDS Marketplace in San Diego. Containing 1,000 mg fish oil, 50 mg CoQ10 and 30 IU of vitamin E, the combo allows for once-per-day use, compared to the 2-3 pills-per-day required by other products, Perrigo maintains. Acidophilus Extra Strength capsules, also launching now, feature a tri-layer system designed to prevent deterioration prior to absorption in the body. The exterior shell protects the product when exposed to air, the secondary shell prevents decay due to stomach acid and the third shell is dissolved in the digestive tract, where the ingredients are released, the private labeler says. Sesame Street Multivitamin Gummies, an extension of the children's line launched last year, also are unveiled (1"The Tan Sheet" June 23, 2003, p. 11). On the OTC side, Perrigo introduces Miconazole 3, the equivalent of J&J's market leading three-day yeast infection therapy Monistat-3. Shipping in July, the product offers three pre-filled applicators...
Perrigo Sees Long-Term Growth In Vitamins; Cough/Cold Sales Down
Perrigo believes the vitamin category provides it with strong prospects for long-term growth despite a significant downturn in the segment's fiscal first quarter sales
Bear Stearns Healthcare Conference In Brief
Ross growth opportunities: Ensure Glucerna nutritional food brand for blood sugar control in people with type 2 diabetes and "other disease-specific nutritionals is an area that offers strong future growth potential for Ross," Tom Freyman, Abbott Labs Senior VP & CFO tells analysts at Bear Stearns Healthcare Conference in New York City on Sept. 8-9. Ross' overall business remains attractive to parent firm Abbott due to its strong cash flow, exceptional return on invested capital, exec notes, adding "our goal now is to improve sales growth" of the division. Ross' ProSure nutritional formula for patients with cancer-induced weight loss has been "well-received in institutions, and the success of our aggressive awareness campaign has resulted in the ability to accelerate the retail strategy," Freyman adds. Abbott recently announced plans to increase its focus, investment on higher margin medical and pharmaceutical products in its portfolio, spin off its hospital products division into a separate publicly traded company (1"The Tan Sheet" Aug. 25, 2003, p. 7)...